Pharmaceutical giant Johnson & Johnson agreed to pay a total of $2.2 billion to settle criminal charges and municipal liability statements for its goods under subsidiary Janssen Pharmaceuticals which contains Risperdal, a top-selling antipsychotic medicine that demonstrated to topic seniors with dementia to an undesirable degree of risk for stroke and other potentially lethal disorders.
The settlement is very substantial, considered the largest to date for any antipsychotic drug. However, because Risperdal was immensely popular with a broad market base, the drug maker a great deal of cash had been made by it before product liability lawsuits started coming in. It is exceedingly likely the pharmaceutical giant can simply take it in stride with small trouble.
This is the point where J&J made a misstep; the medication was vigorously promoted for this purpose, and plaintiffs claim that the firm knew about the health-related hazards it posed to that particular population segment. And because many of express health advantages were being used by these patients to be responsible for the medication or for nursing home care which used employed the medicine, states have joined in the fray with varying levels of success.
Risperdal began well when it recommended for use in schizophrenia, and autism and was authorized in 1993. It was considered not dangerous enough to be administered to children, although there have been well-advertised side results that both sufferers and doctors were not unaware of and regarded satisfactory provided the advantages, except in some occurrences of suicidality and gynecomastia. Risperdal was never approved for managing the behavior of seniors diagnosed with dementia.
More information about Risperdal lawsuit: www.williamskherkher.com/practice-areas/defective-pharmaceuticals/risperdal/